ERC Advanced Grant · 2024
Pharmacological and gene therapy targeting of NMNAT2 for neuroprotection in glaucoma
The goal of this ERC Advanced Grant is to develop clinically translatable neuroprotective strategies for glaucoma by focusing on NAD metabolism. NMNAT2 is a neuron-specific NAD-generating enzyme and is the upstream enzyme that coordinates axon degeneration. The Williams lab is expert in taking basic biological findings in glaucoma to the clinic, and we will leverage our expertise in this space to develop novel clinically translatable therapeutic interventions for glaucoma based on NMNAT2 biology. In Program 1 my team will further our on-going drug development program developing novel compounds targeting NMNAT2 by: (1) Continuing refining medicinal chemistry to develop an oral and injectable…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.